Copyright Reports & Markets. All rights reserved.

USA Live Attenuated Vaccine Market Report 2018

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Definition and Specification
    • 1.2 Report Overview
      • 1.2.1 Manufacturers Overview
      • 1.2.2 Regions Overview
      • 1.2.3 Type Overview
      • 1.2.4 Application Overview
    • 1.3 Industrial Chain
      • 1.3.1 Live Attenuated Vaccine Overall Industrial Chain
      • 1.3.2 Upstream
      • 1.3.3 Downstream
    • 1.4 Industry Situation
      • 1.4.1 Industrial Policy
      • 1.4.2 Product Preference
      • 1.4.3 Economic/Political Environment
    • 1.5 SWOT Analysis

    2 Market Analysis by Types

    • 2.1 Overall Market Performance(Volume)
      • 2.1.1 Pneumococcal Market Performance (Volume)
      • 2.1.2 Influenza Market Performance (Volume)
      • 2.1.3 HPV Market Performance (Volume)
      • 2.1.4 Hepatitis Market Performance (Volume)
      • 2.1.5 Rotavirus Market Performance (Volume)
    • 2.2 Overall Market Performance(Value)
      • 2.1.1 Pneumococcal Market Performance (Value)
      • 2.1.2 Influenza Market Performance (Value)
      • 2.1.3 HPV Market Performance (Value)
      • 2.1.4 Hepatitis Market Performance (Value)
      • 2.1.5 Rotavirus Market Performance (Value)

    3 Product Application Market

    • 3.1 Overall Market Performance (Volume)
      • 3.1.1 Hospital Market Performance (Volume)
      • 3.1.2 Medical Center Market Performance (Volume)
      • 3.1.3 Others Market Performance (Volume)

    4 Manufacturers Profiles/Analysis

    • 4.1 Astellas Pharma Inc
      • 4.1.1 Astellas Pharma Inc Profiles
      • 4.1.2 Astellas Pharma Inc Product Information
      • 4.1.3 Astellas Pharma Inc Live Attenuated Vaccine Business Performance
      • 4.1.4 Astellas Pharma Inc Live Attenuated Vaccine Business Development and Market Status
    • 4.2 CSL Limited
      • 4.2.1 CSL Limited Profiles
      • 4.2.2 CSL Limited Product Information
      • 4.2.3 CSL Limited Live Attenuated Vaccine Business Performance
      • 4.2.4 CSL Limited Live Attenuated Vaccine Business Development and Market Status
    • 4.3 Emergent BioSolutions
      • 4.3.1 Emergent BioSolutions Profiles
      • 4.3.2 Emergent BioSolutions Product Information
      • 4.3.3 Emergent BioSolutions Live Attenuated Vaccine Business Performance
      • 4.3.4 Emergent BioSolutions Live Attenuated Vaccine Business Development and Market Status
    • 4.4 GlaxoSmithKline
      • 4.4.1 GlaxoSmithKline Profiles
      • 4.4.2 GlaxoSmithKline Product Information
      • 4.4.3 GlaxoSmithKline Live Attenuated Vaccine Business Performance
      • 4.4.4 GlaxoSmithKline Live Attenuated Vaccine Business Development and Market Status
    • 4.5 Johnson&Johnson
      • 4.5.1 Johnson&Johnson Profiles
      • 4.5.2 Johnson&Johnson Product Information
      • 4.5.3 Johnson&Johnson Live Attenuated Vaccine Business Performance
      • 4.5.4 Johnson&Johnson Live Attenuated Vaccine Business Development and Market Status
    • 4.6 MedImmune
      • 4.6.1 MedImmune Profiles
      • 4.6.2 MedImmune Product Information
      • 4.6.3 MedImmune Live Attenuated Vaccine Business Performance
      • 4.6.4 MedImmune Live Attenuated Vaccine Business Development and Market Status
    • 4.7 Merck
      • 4.7.1 Merck Profiles
      • 4.7.2 Merck Product Information
      • 4.7.3 Merck Live Attenuated Vaccine Business Performance
      • 4.7.4 Merck Live Attenuated Vaccine Business Development and Market Status
    • 4.8 Pfizer
      • 4.8.1 Pfizer Profiles
      • 4.8.2 Pfizer Product Information
      • 4.8.3 Pfizer Live Attenuated Vaccine Business Performance
      • 4.8.4 Pfizer Live Attenuated Vaccine Business Development and Market Status
    • 4.9 Sanofi Pasteur
      • 4.9.1 Sanofi Pasteur Profiles
      • 4.9.2 Sanofi Pasteur Product Information
      • 4.9.3 Sanofi Pasteur Live Attenuated Vaccine Business Performance
      • 4.9.4 Sanofi Pasteur Live Attenuated Vaccine Business Development and Market Status

    5 Market Performance for Manufacturers

    • 5.1 USA Live Attenuated Vaccine Sales (K Units) and Market Share by Manufacturers 2013-2018
    • 5.2 USA Live Attenuated Vaccine Revenue (M USD) and Market Share by Manufacturers 2013-2018
    • 5.3 USA Live Attenuated Vaccine Price (USD/Unit) of Manufacturers 2013-2018
    • 5.4 USA Live Attenuated Vaccine Gross Margin of Manufacturers 2013-2018
    • 5.5 Market Concentration

    6 Regions Market Performance for Manufacturers

    • 6.1 Northeast Market Performance for Manufacturers
      • 6.1.1 Northeast Live Attenuated Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.1.2 Northeast Live Attenuated Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.1.3 Northeast Live Attenuated Vaccine Price (USD/Unit) of Manufacturers 2013-2018
      • 6.1.4 Northeast Live Attenuated Vaccine Gross Margin of Manufacturers 2013-2018
      • 6.1.5 Market Concentration
    • 6.2 Midwest Market Performance for Manufacturers
      • 6.2.1 Midwest Live Attenuated Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.2.2 Midwest Live Attenuated Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.2.3 Midwest Live Attenuated Vaccine Price (USD/Unit) of Manufacturers 2013-2018
      • 6.2.4 Midwest Live Attenuated Vaccine Gross Margin of Manufacturers 2013-2018
      • 6.2.5 Market Concentration
    • 6.3 South Market Performance for Manufacturers
      • 6.3.1 South Live Attenuated Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.3.2 South Live Attenuated Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.3.3 South Live Attenuated Vaccine Price (USD/Unit) of Manufacturers 2013-2018
      • 6.3.4 South Live Attenuated Vaccine Gross Margin of Manufacturers 2013-2018
      • 6.3.5 Market Concentration
    • 6.4 West Market Performance for Manufacturers
      • 6.4.1 West Live Attenuated Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.4.2 West Live Attenuated Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.4.3 West Live Attenuated Vaccine Price (USD/Unit) of Manufacturers 2013-2018
      • 6.4.4 West Live Attenuated Vaccine Gross Margin of Manufacturers 2013-2018
      • 6.4.5 Market Concentration

    7 USA Live Attenuated Vaccine Market Performance (Sales Point)

    • 7.1 USA Live Attenuated Vaccine Sales (K Units) and Market Share by Regions 2013-2018
    • 7.2 USA Live Attenuated Vaccine Revenue (M USD) and Market Share by Regions 2013-2018
    • 7.3 USA Live Attenuated Vaccine Price (USD/Unit) by Regions 2013-2018
    • 7.4 USA Live Attenuated Vaccine Gross Margin by Regions 2013-2018

    8 Development Trend for Regions (Sales Point)

    • 8.1 USA Live Attenuated Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.2 Northeast Live Attenuated Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.3 Midwest Live Attenuated Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.4 South Live Attenuated Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.5 West Live Attenuated Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018

    9 Upstream Source, Technology and Cost

    • 9.1 Upstream Source
    • 9.2 Technology
    • 9.3 Cost

    10 Channel Analysis

    • 10.1 Market Channel
    • 10.2 Distributors

    11 Consumer Analysis

    • 11.1 Hospital Industry
    • 11.2 Medical Center Industry
    • 11.3 Others Industry

    12 Market Forecast 2019-2024

    • 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
      • 12.1.1 USA Live Attenuated Vaccine Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
      • 12.1.2 USA Live Attenuated Vaccine Sales (K Units) and Growth Rate 2019-2024
      • 12.1.3 Northeast Live Attenuated Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.4 Midwest Live Attenuated Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.5 South Live Attenuated Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.6 West Live Attenuated Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.7 Live Attenuated Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.8 Live Attenuated Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.9 Live Attenuated Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.10 Live Attenuated Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    • 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
      • 12.3.1 Overall Market Performance
      • 12.3.2 Pneumococcal Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.3 Influenza Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.4 HPV Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.5 Hepatitis Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    • 12.4 Sales by Application 2019-2024
      • 12.4.1 Overall Market Performance
      • 12.4.2 Hospital Sales and and Growth Rate 2019-2024
      • 12.4.3 Medical Center Sales and and Growth Rate 2019-2024
      • 12.4.4 Others Sales and and Growth Rate 2019-2024
    • 12.5 Price (USD/Unit) and Gross Profit
      • 12.5.1 USA Live Attenuated Vaccine Price (USD/Unit) Trend 2019-2024
      • 12.5.2 USA Live Attenuated Vaccine Gross Profit Trend 2019-2024

    13 Conclusion

    Geographically, this report split USA into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Live Attenuated Vaccine for these regions, from 2012 to 2023 (forecast), including
    Northeast
    Midwest
    South
    West

    USA Live Attenuated Vaccine market competition by top manufacturers/players, with Live Attenuated Vaccine sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Astellas Pharma Inc
    CSL Limited
    Emergent BioSolutions
    GlaxoSmithKline
    Johnson&Johnson
    MedImmune
    Merck
    Pfizer
    Sanofi Pasteur

    On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
    Pneumococcal
    Influenza
    HPV
    Hepatitis
    Rotavirus
    DTP
    Polio
    MMR

    On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Live Attenuated Vaccine for each application, including
    Hospital
    Medical Center
    Others

    If you have any special requirements, please let us know and we will offer you the report as you want.

    Buy now